Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of AbiVERtinib in Combination With Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (Maverick Trial)

NCT05361915 is registered in ClinicalTrials.gov with Sorrento Therapeutics, Inc. as lead sponsor.

NCT NCT05361915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05361915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of AbiVERtinib in Combination With Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (Maverick Trial)
Lead sponsor
Sorrento Therapeutics, Inc.
Phase
Phase 2
Overall status
Suspended
Start date
September 30, 2025
Completion date
January 31, 2028
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer metastatic